drugset / Trial / NCT03611595
Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study is being conducted in order to determine the safety, dose-limiting toxicities, and maximum tolerated dose of cabozantinib in combination with 13-cis-retinoic acid in patients with relapsed or refractory solid tumors including tumors of the central nervous system (CNS)
Timeline
- Start
- 2018-08-28
- Primary completion
- 2026-02-24
- Completion
- 2026-03-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | — | Oral |
| Subject | Isotretinoin | Other / unclassified | 80 mg/m2 | — |